Intra-cellular Therapies, Inc.

This study tested the safety and how the body processes a medication called lumateperone in teenagers with schizophrenia or schizoaffective disorder. It involved 26 participants aged 13 to 17. The main goal was to understand the drug's side effects and how it moves through the bo…

This study tested whether a medication called ITI-007 (Lumateperone) helps reduce depression symptoms in people with bipolar disorder. Researchers enrolled 554 adults with bipolar I or II disorder who were experiencing a depressive episode. Participants received either the medica…

This study tested whether a medication called ITI-007 could help control symptoms in people experiencing a schizophrenia flare-up. Researchers compared the drug against a placebo in 450 adults with schizophrenia over 28 days. They measured changes in symptoms like hallucinations,…

This study aimed to check the long-term safety of adding a new medication called lumateperone to standard antidepressant therapy for people with major depression. Over 800 patients who had already completed a prior study took lumateperone daily for about six months while continui…

This large Phase 3 study tested whether a new medication called ITI-007 could help control symptoms in people experiencing a sudden worsening of schizophrenia. For 6 weeks, 696 adult patients received either ITI-007, an existing antipsychotic medication, or a placebo pill, with n…

This study tested whether a new drug called ITI-007 could reduce symptoms in people with schizophrenia who were experiencing a sudden worsening of their psychosis. 335 participants were randomly assigned to receive either one of two doses of ITI-007, a placebo (inactive pill), or…

This early study aimed to understand how a new drug called ITI-333 works in the brain. Researchers gave single doses to 12 healthy volunteers and used special brain scans to see how much of the drug attached to its target. They also checked how the body processed the drug and mon…

This early-stage study aimed to understand the safety and how the body processes a new drug called ITI-333. It involved 32 healthy volunteers who received either the drug or a placebo daily for two weeks. The main goals were to check for side effects and measure how the drug move…